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Abstract  
Background 
Barrett’s oesophagus predisposes to adenocarcinoma. However, most Barrett’s 
patients will not progress and endoscopic surveillance is invasive, expensive, and 
fraught by issues of sampling bias and the subjective assessment of dysplasia. This 
study investigated whether a non-endoscopic device, the Cytosponge, could be 
coupled with clinical and molecular biomarkers to identify a low-risk group for non-
endoscopic follow-up. 
Methods 
In this multicentre cohort study (BEST2), patients with Barrett’s underwent the 
Cytosponge test prior to their surveillance endoscopy. Clinical and demographic data 
were collected and Cytosponge samples were tested for a molecular biomarker 
panel including three protein biomarkers (p53, c-Myc, and Aurora kinase A), two 
methylation markers (MYOD1 and RUNX3), glandular atypia and TP53 mutation 
status. A multivariable logistic regression model was used to compute the 
conditional probability of dysplasia status. A simple model with high classification 
accuracy was selected and applied to an independent validation cohort.  
Findings 
In a discovery cohort (n=468) a model with high classification accuracy consisted of: 
glandular atypia, p53 abnormality and Aurora kinase A positivity and the interaction 
of age, obesity and length of the Barrett’s segment. 35% patients fell into the low-
risk category and the probability of being a true non-dysplastic patient was 162/162 
(Confidence Intervals at 0.01 significance level 96-99·99%). In the validation cohort 
(n=65) 25/65 patients (38%) were classified as low risk and the probability of being a 
true non-dysplastic was 96·0% (99% CI 73·8-99·99%). The moderate-risk group 
comprised 27 non-dysplastic and 8 high grade dysplasia (HGD) cases while the high 
risk group had 0 non-dysplastic and 5 HGD patients (8% cohort).  
Interpretation 
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A combination of biomarker assays from a single Cytosponge sample can be used to 
determine a group of patients at low risk for whom endoscopy could be avoided. 
This strategy could help to avoid over-diagnosis and over-treatment in Barrett’s 
patients. 
Funding 
The BEST2 study was funded by Cancer Research UK.  
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Research in context 
Evidence before the study 
We searched PubMed from database inception to September 1st, 2001 with the 
MESH terms: biomarkers, cancer progression, Barrett’s oesophagus prior to the start 
of the BEST2 trial, in order to review the status of the literature. This important area 
has attracted a lot of attention and aside from the histopathological assessment of 
dysplasia the most promising biomarkers include p53 status, copy number 
alterations and recently methylation panels have been investigated. All of these 
studies have relied on endoscopic sampling which is invasive and resource intensive. 
Furthermore, most effort has focussed on identifying patients at high risk for cancer. 
However since the majority will not progress to cancer, strategies to risk-stratify 
patients and avoid over-diagnosis are also very important. Furthermore, given the 
heterogeneity in the molecular genetic patient profiles of those progressing to 
cancer, identifying very low risk patients may be a more achievable biomarker 
strategy. A non-endoscopic cell collection device (Cytosponge) has been shown to be 
effective to diagnose Barrett’s when coupled with a biomarker TFF3. The aim of this 
study was to determine whether additional biomarkers could identify patients at 
very low risk in whom further monitoring could be performed via the Cytosponge. 
Endoscopy and treatment could then focus on the highest risk patients.  
Added value of the study 
We tested a clinical and molecular biomarker panel on Cytosponge samples (7 
variables) and used multivariable logistic regression to identify a minimal panel that 
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could risk stratify patients. The optimal panel comprises: age, length of Barrett’s 
segment, waist:hip ratio and three biomarkers scored in a binary fashion to indicate 
p53 status, Aurora kinase A expression and glandular atypia and divides patients into 
low, moderate and high risk. This risk score was validated in an independent patient 
cohort and shown to confidently identify approximately 30% patients with a low risk 
for malignant progression. The high and moderate risk patients would be triaged for 
endoscopy which could be prioritised accordingly. To the best of our knowledge this 
is the first multidimensional panel applied to non-endoscopic oesophageal cell 
samples (ie, one involving DNA mutation, protein expression and clinical variables) to 
determine the risk profile for a patient with Barrett’s oesophagus. 
Implications of the evidence 
Currently monitoring of patients with diagnosed Barrett’s relies on endoscopy which 
is invasive for patients and expensive for the health care system. The use of a 
Cytosponge-biomarker test has the potential to more objectively risk stratify 
patients and identify a low-risk group for monitoring within the primary care setting 
that could be spared endoscopy.  
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Introduction 
Oesophageal adenocarcinoma (OAC) patients have a median survival of one year, 
despite advances in therapy.1 The burden of OAC could be reduced by diagnosing 
more cases of the precursor lesion Barrett’s oesophagus (BO) while identifying those 
at increased risk for cancer development before treating them endoscopically.2 
However, this is a formidable task since the incidence of gastro-oesophageal reflux is 
approximately 5 per 1000 person-years in the UK.3 Furthermore, despite clinical 
guidelines for endoscopic referral, primary care practice varies and low endoscopy 
referral rates correlate with poor outcomes.4 The scale of the problem and the 
psychological and fiscal costs of endoscopy necessitate a new strategy. 
We have developed a non-endoscopic diagnostic test which involves a cell-collection 
device which, coupled with the biomarker trefoil factor 3 (TFF3), diagnoses BO.5,6 The 
device, called Cytosponge, comprises a medical-grade foam sphere on a string 
compressed within a gelatine capsule that is swallowed whilst holding onto the 
string. After 5 minutes, this dissolves within the stomach allowing the foam sphere 
to expand, before being pulled from the stomach through the oesophagus to the 
mouth. Cells are collected along the entire oesophageal lining, minimising the 
sampling bias inevitable with endoscopic biopsies. The sample is transported to the 
laboratory in preservative at room temperature and processed to paraffin for TFF3 
biomarker assessment. Data from studies so far, amounting to over 2,000 patients, 
have shown that this approach is safe, has favourable acceptability rates compared 
to endoscopy, a sensitivity of 79·5-87% (depending Barrett’s segment length), and a 
specificity of 92·4% for diagnosing BO.5,6 
For TFF3-positive patients, it is essential that additional biomarkers are tested to 
assess the presence of genetic or molecular abnormalities indicative of dysplasia, as 
positive tests in patients with very benign disease at low risk of progression are 
commonplace in early cancer detection.7 Over-diagnosis and over-treatment have 
adverse consequences for both patient and healthcare providers.8 Our primary goal 
is thus to identify Barrett’s patients with a very low risk profile, so that these 
individuals can be reassured without endoscopy.  
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We have shown that TP53 mutations qualify for a risk stratification biomarker and 
are detectable using the Cytosponge.9 We have also shown that the Cytosponge-
sample is representative of the multiple clones within a diverse genetic content.10 
However, for a risk-stratification tool to be clinically applicable, it is important not to 
miss patients with high grade dysplasia (HGD) and intramucosal adenocarcinoma 
(IMC). Although TP53 mutation has a high specificity, it will not identify all patients 
with HGD or early cancer, since the prevalence is 70-80%.9,11 To increase our 
sensitivity for detecting high-risk Barrett’s patients, we propose including additional 
molecular biomarkers combined with clinical factors.   
Histopathological grade of dysplasia is a good predictor when confirmed by 
independent pathologists,12 so we included a measure of glandular atypia present 
within the Cytosponge sample. c-Myc was included as it is recurrently amplified in 
OAC,15 while many of its target genes have been identified as overexpressed in 
Barrett’s with dysplasia.15 Copy number change is a strong predictor of progression 
and changes dramatically in the transition to invasive disease.10,16,17 Due to the 
infeasibility, expense and low sensitivity of performing cell cycle analysis or SNP 
arrays on FFPE Cytosponge material, we selected immunohistochemical expression 
of Aurora kinase A (AurKA) as a surrogate aneuploidy marker.18 AurKA expression 
has also been shown to be significantly upregulated in Barrett’s with HGD and OAC 
compared to non-dysplastic.19  
In addition to TP53 sequencing, p53 staining was included as this has been shown to 
be associated with dysplasia,20 although the p53 staining-absent pattern cannot be 
reliably scored on the Cytosponge samples and was excluded. Recent evidence has 
shown that methylation is a good predictor of progression.22 Five genes shown to be 
methylated with increasing grade of dysplasia were tested: p16, ESR1, MYOD1, 
HPP1, and RUNX3.21 After reviewing pilot data, only MYOD1 and RUNX3 were taken 
forward, as these were the most promising (See Appendix, p3). 
In summary, the tissue biomarkers taken forward into this study were therefore: 
atypia, AurKA, p53 abnormality (mutations and protein over-expression), c-Myc 
overexpression, MYOD1 and RUNX3 methylation (Appendix, p3). Clinical information 
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including demographics and symptoms were also assessed as additional biomarkers 
of risk. 
 
Hence, the study aims were: to identify a clinically applicable risk-stratification 
biomarker panel which could be performed on the Cytosponge samples; - to apply 
this panel to a large cohort of patients with BO and a TFF3-positive Cytosponge 
sample to confidently identify a low-risk group of at least 30% of cases who could be 
spared endoscopy; and - to test the Cytosponge risk-stratification model on an 
independent cohort of patients. 
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Methods: 
Study design and participants 
The prospective, multi-centre BEST2 case-control cohort was designed to examine 
risk stratification in the Barrett’s (case) arm as a secondary objective.6 Ethics 
approval was obtained from the East of England–Cambridge Central Research Ethics 
Committee (No: 10/H0308/71) and registered in the UK Clinical Research Network 
Study Portfolio (9461). Patients in the validation cohort were selected from newly 
registered BEST2 patients and from the CASE1 study (see Appendix, p4).22 Earliest 
date of enrolment for participants was 07/07/2011. Written informed consent was 
obtained for each patient. Data was collected on demographics, clinical exposures 
(alcohol, tobacco, drugs), and symptoms and anonymised. We collected W:H ratio 
and BMI in the BEST2 study but found that BMI is much more frequently measured 
in clinical practice and is less prone to error. For the validation cohort we therefore 
used BMI only. There was no minimum segment length requirement for BO provided 
they had a least one TFF3 positive cell. Cytosponge specimens were processed to 
paraffin blocks, as previously published.6 The gastroscopies were performed within 
an hour of Cytosponge collection. Biopsy samples were taken from any visible lesions 
and from each quadrant, every 2 cm as recommended by the Seattle surveillance 
protocol. Diagnostic biopsies were reviewed locally. Biopsies with a diagnosis of 
dysplasia were reviewed in a consensus meeting by experienced pathologists from 
four institutions (M.O., M.N., B.D., and P.K.) that were blinded to the Cytosponge 
test result.  
Procedures 
The processed TFF3 positive sample was cut into consecutive sections and the first 
slide containing two sections was stained with H&E.  No enrichment was made for 
TFF3 positive or histopathological atypical areas prior to assessment for molecular 
biomarkers – the entire Cytosponge section was evaluated for each biomarker. 
Any glandular atypia present on this slide was assessed by two expert pathologists 
(M.O. and S.M.) blinded to the clinical diagnosis and a consensus reached (Kappa 
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0.66). For protein biomarker immunohistochemistry (IHC), slide 4 was used for p53, 
slide 8 for c-Myc and slide 10 for AurKA.  Slides were stained using the BondMax 
autostainer with the Leica Bond Polymer Detection kit.  The conditions and 
antibodies used can be found in the Appendix, p5.   
p53 staining with an intensity of 3 was considered significant, as previously 
published.20 c-Myc intensity was scored as 0-3 with 2 and 3 being considered 
significant staining.23 As p53 is most commonly scored in a binary fashion and also 
due to the varying amount of Barrett’s tissue in the Cytosponge samples, we decided 
against using a % scoring system. AurKA scoring was determined with a pilot study to 
evaluate different cut-offs and bearing in mind clinical feasibility. Thus AurKA was 
scored as non-significant or significant staining, with non-significant being fewer 
than 5 positive-staining cells, in the whole section.  
Genomic DNA was extracted from 8x10µm sections of the processed Cytosponge 
FFPE clot using Deparaffinization Buffer (Qiagen) and the QIAamp FFPE DNA Tissue 
Kit (Qiagen).  The manufacturer’s protocol was followed with the exception that 
samples were incubated at 56oC for 24 hours instead of 1 hour, and 10 µl of extra 
Proteinase K were added to the samples halfway through the incubation. FFPE-
extracted DNA was quantified by PCR using primers specific to ALU115 repetitive 
elements (See Appendix, p1). 10-25ng quantified DNA was used for library 
preparation using TP53 Accel-Amplicon comprehensive panel (Swift Biosciences) 
according to manufacturer’s guidelines and sequenced on the Illumina Miseq 
machine using 150bp paired-end sequencing to achieve an average of 10,000-fold 
coverage per sample. 
Outcomes 
Sequencing quality was checked using the FastQC program.  Trimmed reads were 
aligned to GRCh37 human reference genome (hg19) using BWA aligner, then sorted 
by genomic positions and processed using the GATK pipeline. The GRCh38 version 
was not available when we started this work. We used LoFreq to detect low allele-
frequency variants from the Cytosponge samples and annotated the results using 
VEP command from ensembl database. Libraries were prepared in duplicate for each 
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sample and mutations called in both duplicates with an allele frequency above 0·5% 
were considered as true positives.  
DNA was bisulphite-converted using the EZ DNA Methylation-Gold™ kit (as described 
by Zymo Research).  Samples were eluted in 25 µl water and 2 µl was used per 
MethyLight reaction, as previously described.24 β-actin was used to normalise for 
amount of input DNA. Universally methylated and bisulphite-converted DNA (D5010-
1, Zymo Research) was used to derive standard curves for each primer and probe set 
and a calibrator was used in all experiments to allow absolute quantification of 
methylation levels.  Amplification conditions used for all reactions were: 95oC for 10 
mins followed by 50 cycles of 95oC for 15 seconds and 60oC for 1 minute. Percentage 
methylation of each gene was calculated as previously published,17 as was the 
combined methylation value for RUNX3 plus MYOD1. The data underlying our choice 
of these 2 biomarkers is shown in the Appendix, p3.  
Statistical analysis 
The histopathological diagnosis from the endoscopy biopsy taken at the same time 
as the Cytosponge was used as the gold standard for comparison. Data analysis was 
performed using R statistical software version 3.0.2,31 and missing values were 
imputed using iterative regression imputation.32 A logistic regression model was 
used to compute the conditional probability to have Barrett’s with high grade 
dysplasia/intramucosal adenocarcinoma (HGD/IMC), given the covariates. Consider a 
simple decision theory problem. Rather than modelling the dichotomous response 
variable Y directly (Best2diagnosis; 1: HGD/IMC, 0: Negative), we modelled the 
probability that Y belongs to a particular category, given the value of p covariates, 
say X={X1,…,Xp}. We classified samples based on estimating the conditional 
probabilities p(Y|X) and then predicted the risk-profile of a patient as follows: 
 Low-risk if p(Y=1|X) <= c1 
 Moderate-risk if c1 < p(Y=1|X) < c2 
 High-risk if p(Y=1|X) >= c2 
where c1 and c2 are estimated from the data (see Appendix, p1). A model consisted 
of glandular atypia, p53 abnormality, Aurora kinase A IHC and the interaction of BMI 
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(or waist:hip ratio), Barrett’s oesophagus maximum length and age was selected. The 
model with BMI is preferable clinically.  Estimated model coefficients and confidence 
intervals are provided in the Appendix, page 1. Clopper-Pearson Binomial confidence 
intervals for proportions are provided. 
Role of the funding source 
The BEST2 study was funded by Cancer Research UK. (Grant ref; C14478/A12088, 
http://www.cancerresearchuk.org/). The funders had no role in study design, data 
collection, analysis and interpretation, decision to publish, or writing of the report. 
The study received infrastructure support from the Cambridge Human Research 
Tissue Bank, which is supported by the National Institute for Health Research (NIHR) 
Cambridge Biomedical Research Centre, from Addenbrooke’s Hospital. R.C.F. is 
funded by an NIHR Professorship and receives core funding from the Medical 
Research Council and infrastructure support from the Biomedical Research Centre 
and the Experimental Cancer Medicine Centre. R.C.F. and C.S.R. had full access to all 
the data in the study. The corresponding author had the final responsibility to 
submit for publication.  
Results 
Patient characteristics 
TFF3-positive Cytosponge samples from 468 Barrett’s patients with intestinal 
metaplasia were assessed.  Of these, 376 had no dysplasia and 92 had HGD/IMC 
(Figure 1).  Patients with HGD/IMC were older (Mann-Whitney test, p<0.0001), had 
longer Barrett’s segments (p<0.0001) and had a higher waist:hip ratio (p=0.008) 
(Table 1).  
Biomarker panel performance  
Seven biomarkers, including three protein biomarkers for p53, c-Myc, and AurKA 
(Figure 2), two methylation markers (MYOD1 and RUNX3), glandular atypia and TP53 
mutation were assessed on all 468 Cytosponge samples with very few assays failing 
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and resulting in missing data (Table 2). All biomarkers were analysed separately to 
estimate their sensitivity and specificity for detecting HGD/IMC compared to no 
dysplasia on the Cytosponge specimen. A positive value for p53 abnormality resulted 
from either significant p53 staining or TP53 mutation. The combined methylation 
value for MYOD1 and RUNX3 was also analysed (Table 2). AurKA IHC was the most 
sensitive biomarker (78%; 65-88%) for detecting HGD/IMC compared to no dysplasia. 
p53 IHC was the most specific biomarker (96%; 92-98%) p53 IHC and TP53 mutation 
alone both had sensitivities of 58% (44-70%), but combining these increased 
sensitivity to 72% (58-83%) (Table 2).  
No biomarkers were sensitive and specific enough individually.  As our main aim was 
to identify a low-risk group who would be spared endoscopy, we performed a 
multivariable logistic regression analysis considering all biomarkers and a list of 
demographic information, clinical exposures (smoking, alcohol, medication), 
symptoms, and endoscopic findings (see Appendix, p6) to identify such a group.  
Using a 3-risk model approach (low-, moderate-, and high-risk), we selected the 
smallest possible number of predictors that attained the best possible specificity. 
The model with the best classification performance consisted of four predictors, with 
coefficient estimate shown in brackets: glandular atypia (2.435), p53 abnormality 
(1.802), AurKA IHC (0.876), and the interaction of age, waist:hip ratio, and maximum 
Barrett’s segment length (0.0000634). Atypia and a positive AurKA score were 
associated with a longer segment length (Wilcox text p=<0.0001) and p53 status to a 
lesser extent (p=0.002), (Appendix, p10). 
Testing this model on the full cohort resulted in all HGD/IMC Barrett’s patients being 
categorised as moderate- or high-risk (Figure 3 and Table 3). For the low-risk 
category, the probability of being truly non-dysplastic was 162/162 (Confidence 
Interval at 0.01 significance level 96-100%) and the probability of being a HGD/IMC 
patient was 0/162 (0·01-4%). Furthermore, given a patient has HGD/IMC, the 
probability of this sample being classified as low-risk was less than 5·6%. For the 
moderate-risk group, the probability of being truly non-dysplastic was 86% (79-91%) 
and the probability of being a true HGD/IMC was 14% (9-21%). For high-risk patients, 
the probability of being a true HGD/IMC was 87% (73-95%) and the probability of 
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having non-dysplastic endoscopic biopsies was 13% (5-27%). Analysis of clinical data 
on the non-dysplastic patients misclassified as high-risk determined that one patient 
was diagnosed with metastatic adenocarcinoma, two had HGD/IMC requiring 
endoscopic therapy, two had an endoscopic diagnosis of indefinite for dysplasia and 
remain under follow-up, while the remaining 5 have not yet developed dysplasia.  
Next, we checked the model in a cohort of 65 patients, with baseline characteristics 
similar to the discovery cohort (Table 1). 25/65 patients (38%) were classified as low-
risk and these included 24 non-dysplastic cases and 1 with HGD (Table 3). Hence, if 
categorised as low-risk, the probability of being truly non-dysplastic was 96·0% 
(99%;73·8-99·99%). There were 27 non-dysplastic and 8 HGD cases classified as 
moderate-risk which made up 54% of the cohort and the high-risk group comprised 5 
HGD and no non-dysplastic patients (8% cohort).  
Low grade dysplasia (LGD) is a difficult histopathological diagnosis with low inter 
intra-observer variability and variable outcomes12, so including them in the model 
from the start could cause confounding. We therefore analysed them separately. 
Out of 50 patients with LGD diagnosed from endoscopic biopsies taken on the same 
day as the Cytosponge, 16 were categorised as high-risk, 29 as moderate-risk and 5 
as low-risk. Since a diagnosis of LGD is now a clinical indication for endoscopic 
ablation therapy, following evidence for the superiority of ablation therapy 
compared with surveillance,13 it is impossible to assess the patients’ natural history. 
However, we also examined how the diagnosis related to the highest grade of 
dysplasia ever recorded in these  patients with LGD at the time of the Cytosponge 
and found that 7/16 (44%) patients in the high-risk category had a diagnosis of 
HGD/IMC on endoscopic biopsies taken before or after the Cytosponge test. This was 
more likely than in LGD patients assigned to the moderate or low-risk groups – 7/29 
(24%) and 1/5 (20%), respectively (Appendix, p7). We also examined the treatment 
offered to these patients as a surrogate for the severity of disease: patients 
categorised as high risk were more likely to require surgical or endoscopic resection 
in addition to ablation therapy (Figure 4). 
Discussion  
 16 
 
This study demonstrates the possibility of performing a combination of biomarker 
assays from a single Cytosponge sample. Combining the biomarkers (p53 
abnormality, glandular atypia, and AurKA staining) with clinical variables (age, length 
of Barrett’s, and obesity), and using logistic regression enables us to risk-stratify 
patients into three risk groups. The primary objective was to determine with high 
confidence a group of patients at low risk for whom endoscopy could be avoided. 
The validation cohort suggests that the algorithm provides a high level of confidence 
(74-99% confidence intervals) for determining patients who are dysplasia-free. In 
both discovery and validation, approximately one third of patients fell into the low-
risk category which could have a substantial impact on the financial and 
psychological burden for this group. High-risk patients should be prioritised for 
endoscopy and endoscopic therapy if dysplasia is confirmed. For moderate-risk 
patients an endoscopy would be recommended, though in the future a repeat 
Cytosponge might be an alternative given that the natural history of BO is generally 
slow and we have previously shown that repeating the Cytosponge improves 
sensitivity for biomarkers.6 
Current practice relies on subjective histopathological assessment of dysplasia.20 The 
latest UK BSG guidelines suggest using p53 IHC to help improve diagnostic 
confidence, and further studies have strengthened the evidence for this,20 although 
this practice is not yet widely adopted. In the risk score developed here we use 
several objective measures, but also include pathologists’ assessment of glandular 
atypia. The p53 status is based on both whole-gene sequencing as well as an 
immunoscore. We sequenced most coding exons (E2-11) and did not rely on TP53 
hotspot analysis, since sequencing has demonstrated that mutations can occur 
anywhere along the gene.9 The AurKA staining is used as a surrogate for copy 
number and the scoring is binarised to make it as straightforward as possible. 
Currently, clinical features are excluded from clinical assessment of patients 
undergoing surveillance, although Barrett’s segment length is a well-recognised risk 
factor.27 The relevant contribution of individual biomarkers to the risk prediction 
varies, with glandular atypia and p53 status being the most important (see Appendix, 
p8).   
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We restricted the main analyses in the discovery and validation cohorts to 
distinguish between non-dysplastic Barrett’s and HGD, because LGD is a diagnostic 
conundrum. Recent studies have shown that the outcome of a LGD diagnosis can 
vary considerably depending on whether or not the diagnosis was confirmed by 
multiple pathologists at different institutions.29 When we performed the risk 
stratification panel on patients with LGD, we found that patients fell into all three 
risk categories. These cases had all been reviewed by at least two pathologists. 
Unsurprisingly, these cases therefore mainly (88%) fell into the moderate and high-
risk categories, in keeping with previous studies in which a consensus diagnosis of 
LGD has a higher risk of malignant progression.12 It is interesting that in our study 
LGD patients in the high-risk category were more likely to have a diagnosis of 
HGD/IMC at some time during their endoscopic history and to harbour a visible 
lesion, suggesting that the risk category is meaningful. 
The question arises as to how clinically applicable the risk score would be. We did 
not perform any enrichment of the Barrett’s cells within the Cytosponge samples 
and we did not normalise any of the biomarkers according to the number of TFF3+ 
cells in order to make this laboratory panel as clinically applicable as possible.  p53 
immunostaining is routine in histopathology for various conditions and automation 
of nuclear scoring is well-described. Sequencing of a single gene, such as p53, is 
becoming common-place in oncology.30 The AurKA stain is cytoplasmic and less 
robust: we have used a binary score to make it as practical as possible and, since this 
contributes the least to the final score, further studies should evaluate whether this 
could be omitted. Our analysis used BMI or waist:hip ratio and we have found that 
these can be used interchangeably: BMI would be preferable clinically, being less 
prone to measurement error. The risk category can be easily calculated (see 
Appendix, p9, and separate Excel file) and this is becoming common in management 
of several conditions, including cardiovascular disease.31 The economics of our 
approach would need to be determined, but avoiding endoscopy and 
histopathological assessment of multiple biopsies could save money and reduce the 
burden of an invasive procedure for patients. 
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There are a number of limitations to our study. Most centres involved are tertiary 
referral centres and so the population studied may not represent a surveillance 
cohort in a general hospital i.e. at higher risk and also may have a different standard 
of care. The number of patients is reasonable for a risk-stratification study but 
testing in larger prospective cohorts is required. Another difficulty is with regards to 
the choice of a gold standard for comparison. We have chosen the grade of dysplasia 
at the endoscopy performed alongside the Cytosponge. Due to sampling error and 
subjective histopathological assessment, this will lead to miscategorisation. 
Consensus pathology review of biopsies taken at the same time as the Cytosponge 
was performed on all cases with dysplastic Barrett’s however this was not feasible 
for the large number of cases without dysplasia which could lead to a false-negative 
gold standard diagnosis. For example, when we examined the patients categorised 
as high-risk by the Cytosponge who had no dysplasia (discovery cohort) or LGD on 
endoscopic biopsies, we found that some of them had had a diagnosis of HGD in an 
endoscopy performed before or soon after the Cytosponge. If you take non 
dysplastic patients at the time of Cytosponge but who had previously had high grade 
dysplasia, i.e. 12 patients - then 4 were high risk, 5 moderate risk and 3 low risk. The 
number of cases with missing biomarker data was very small. However, the sections 
cut for p53 sequencing were done last and in some cases there wasn’t sufficient to 
perform the assay. We hope that collection of long-term follow-up data on these 
patients will provide further confirmation of the value of the Cytosponge risk score.  
We expect that the risk stratification algorithm presented here can be further 
improved by alternative biomarkers. Before incorporating the Cytosponge-biomarker 
test into clinical practice for surveillance, a large randomised clinical trial powered 
according to the data presented here will be required in which patients are allocated 
to a follow-up or treatment strategy based on their Cytosponge result. In our view, 
this innovative strategy combining a non-endoscopic device with a multi-dimensional 
biomarker panel has the potential to improve management of patients with pre-
malignant BO in whom risk stratification is essential to avoid over-diagnosis and 
over-treatment. 
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Table 1: Demographics of the discovery and validation cohorts 
 Discovery cohort Validation cohort 
 Non-dysplastic 
Barrett’s 
oesophagus 
Barrett’s 
oesophagus with 
HGD or IMC 
Non-dysplastic 
Barrett’s 
oesophagus 
Barrett’s 
oesophagus with 
HGD  
Number 376 92 51 14 
Age (years) 64 (56-71) 69 (63-74) 63 (53-69) 62 (49-67) 
Ethnicity 
number (%) 
            
White 
            Other  
            
Refused 
 
366 (97·3%) 
9 (2·4%) 
1 (0·3%) 
 
91 (98·9%) 
1 (1·1%) 
0 (0·0%) 
 
49 (96·1%) 
2 (3·9%) 
0 (0·0%) 
 
14 (100·0%) 
0 (0·0%) 
0 (0·0%) 
Sex (M:F) 3·8 : 1 7·4 : 1 4·1 : 1 13·0 : 1 
BMI 28·1 (25·5-
30·8) 
28.8 (26·1-31·1) 28·1 (25·6-30·4) 27.8 (25·3-31.9) 
Waist:hip 
ratio  
0·94 (0·90-
0·98) 
0.95 (0·93-1·01) Not recorded* Not recorded* 
Hiatus 
hernia (%) 
78·4% 82·0% 86·3% 92·9% 
Barrett’s 
oesophagus 
maximum 
length (cm)  
4 (3-7) 7 (5-10) 4 (3-6) 5 (4-7) 
Data shown reflect median (IQR) for age, BMI, waist:hip ratio and Barrett’s oesophagus maximum 
length. Male: female ratio rounded to the nearest tenth. HGD = high-grade dysplasia, IMC = 
intramucosal adenocarcinoma. 
*Waist:hip ratio was seldom recorded, so only BMI was used for the validation cohort.  
  
 26 
 
Table 2: Sensitivity and specificities estimates for the individual biomarkers comparing non-
dysplastic Barrett’s oesophagus and Barrett’s oesophagus with high grade dysplasia. p53 
abnormality was computed using the combined data for p53 IHC and TP53 mutation (i.e. 
either significant p53 staining or TP53 mutation would give a positive value for p53 
abnormality). Clopper and Pearson Binomial Confidence Intervals are provided for 
dichotomous variables. Logistic regression classification was performed using each of the 
continuous variables. Number of samples with missing data is shown.  
 
  
Biomarker Sensitivity (%) Specificity (%) Missing data (%) 
p53 IHC 58 (44-70) 96 (92-98) 1 (0.2) 
TP53 mutation 58 (44-70) 85 (80-90) 13 (2.8) 
p53 abnormality 72 (58-83) 83 (77-88) 13 (2.8) 
Glandular atypia 64 (50-77) 94 (90-97) 1 (0.2) 
cMyc IHC 63 (49-75) 72 (66-78) 3 (0.6) 
Aurora kinase A IHC 78 (65-88) 70 (64-77) 4 (0.9) 
MYOD1 methylation 67 (61-74) 64 (50-77) 7 (1.5) 
RUNX3 methylation 74 (67-79) 60 (46-73) 7 (1.5) 
Combined MYOD1 and 
RUNX3 methylation 
70 (63-76) 62 (48-75) 7 (1.5) 
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Table 3: Risk classification results for the discovery and validation cohorts. NDBO= Non-
dysplastic Barrett’s oesophagus, HGD= Barrett’s oesophagus with high grade dysplasia, 
IMC=intramucosal adenocarcinoma 
Discovery cohort (n=468) Validation cohort (n=65) 
Risk 
classification 
NDBO  HGD/IMC  Risk 
classification 
NDBO  HGD  
Low (n=162) 162 (43%) 0 (0%) Low (n=25) 24 (47%) 1 (7%) 
Moderate 
(n=238) 
205 (55%) 33 (36%) Moderate 
(n=35) 
27 (53%) 8 (57%) 
High (n=68) 9 (2%) 59 (64%) High (n=5) 0   (0%) 5 (36%) 
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Figure 3: Risk classification results for the 468 discovery cohort patients. Barrett’s 
patients with no dysplasia are depicted by a square and patients with high-grade dysplasia or 
intramucosal adenocarcinoma are depicted by triangles.  
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Appendix: Risk stratification of Barrett's oesophagus using a non-endoscopic 
sampling method coupled with a biomarker panel 
Materials and methods 
FFPE DNA extraction and TP53 sequencing on Cytosponge samples 
The primer sequences specific to ALU115 repetitive elements used for quantification of FFPE 
extracted DNA by PCR were: (forward) 5’-CCTGAGGTCAGGAGTTCGAG-3’ and (reverse) 5’-
CCCGAGTAGCTGGGATTACA-3’. 
Methylation analysis on the Cytosponge 
The sequences of the primers and probes used were: MYOD1 forward primer: 5’-
GAGCGCGCGTAGTTAGCG-3’, MYOD1 reverse primer: 5’-TCCGACACGCCCTTTCC-3’, 
MYOD1 probe: 5’-6FAM-CTCCAACACCCGACTACTATATCCGCGAAA-TAMRA-3’, ACTB 
forward primer: 5’-TGGTGATGGAGGAGGTTTAGTAAGT-3’, ACTB reverse primer: 5’-
AACCAATAAAACCTACTCCTCCCTTAA-3’, ACTB probe: 5’-6FAM-
ACCACCACCCAACACACAATAACAAACACA-TAMRA-3’ (from Eads, Danenberg et al. 2000), 
RUNX3 forward primer: 5’-GGCTTTTGGCGAGTAGTGGTC-3’, RUNX3 reverse primer: 5’-
ACGACCGACGCGAACG-3’, RUNX3 protein: 5’-6FAM-
CGTTTTGAGGTTCGGGTTTCGTCGTT-TAMRA-3’ from the Meltzer laboratory. 
Statistical analysis  
Let Y be the response variable (Best2diagnosis; 1: HGD/IMC, 0: Negative) and X={X1,…,Xp} 
represent p covariates. Recall that we classified samples based on estimating the conditional 
probabilities p(Y|X) using a logistic regression model and then predicted the risk-profile of a patient as 
described in main text, where c1 and c2 are estimated from the data as described below. First, a 
biomarkers logistic regression model (with glandular atypia, p53 abnormality and Aurora kinase A IHC 
as covariates) was selected using a backward model selection approach32. More precisely, we started 
with a model consisting of all biomarkers then the least significant variable was dropped, so long as it 
was not significant at the 0.05 critical level. We proceeded by removing non-significant variables in a 
sequential manner (applying the same rule) until all remaining variables were statistically significant. 
The fitted conditional probabilities of being HGD/IMC were computed using the selected logistic 
regression model and then they were classified in three risk-groups, i.e. low, moderate, and high risk, 
as described above. The lower threshold c1 was selected to maximise (minimise) the number of 
negative (HGD/IMC) samples classified in the low-risk group. The other threshold c2 was selected to 
maximise (minimise) the number of HGD/IMC (negative) samples classified in the high-risk group. In 
an attempt to increase classification accuracy (as defined below), we fitted logistic regression models 
consisting of the selected biomarkers plus an additional covariate representing any of all available 
clinical variables. We have also fitted models including the main effects of clinical features and/or 
second and/or third order interactions between the clinical variables. The classification procedure 
described above was subsequently applied on each fitted model. The predictive performance of each 
model was assessed using the following simple approach. All models were ranked (i) in an ascending 
order according to the total number of misclassified patients (HGD/IMC in low-risk group and negative 
patients in high-risk group) and, subsequently, (ii) in a descending order based on the total number of 
correctly classified patients (negative patients falling into the low-risk group and HGD/IMC patients 
falling into the high-risk group). In this fashion, the higher the ranking of a model is, the better 
predictive performance is supposed to have. A model consisted of glandular atypia, p53 abnormality, 
Aurora kinase A IHC and the interaction of BMI (or waist:hip ratio), Barrett’s oesophagus maximum 
length and age was selected. We are aware of the increased chance of overfitting, thus we emphasized 
on enrolling a validation cohort to assess the “out-of-sample” performance and get more trustworthy 
results. The predictive performance of the selected model on the validation cohort seems promising.     
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Estimated model coefficients, standard errors, z-statistics and p-values are provided below: 
Coefficient Estimate Std. Error Z-value P-value 
Intercept -4.019 0.384 -10.471 <0.00000000000000002 
Atypia 2.435 0.362 6.732 0.000000000017 
p53_Status 1.802 0.325 5.544 0.00000003 
AURKA 0.876 0.340 2.574 0.01005 
AgexMxBMI 0.0000634 0.000022 2.885 0.00392 
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Tables 
Sensitivity and specificity assessment of methylated regions to detect dysplasia on the 
Cytosponge. 
In a pilot experiment consisting of 113 Cytosponge samples (15 controls,  54 Barrett’s with no 
dysplasia, 20 Barrett’s with LGD and 24 Barrett’s with HGD), five methylated regions (p16, HPP1, 
RUNX3, ESR1 and MYOD1) were assessed to see which subset of methylated regions performed the 
best and had the best sensitivity and specificity to detect dysplasia on the Cytosponge.  Together 
RUNX3 and MYOD1 gave the best area under the curve when comparing any dysplasia with no 
dysplasia and were therefore taken forward to evaluate further on the Cytosponge samples.   
 
Methylation regions AUC 
ESR1 0.739 
HPP1 0.754 
MYOD1 0.771 
P16 0.673 
RUNX3 0.754 
P16 HPP1 0.757 
P16 RUNX3 0.727 
P16 ESRI 0.741 
P16 MYOD1 0.762 
HPP1 RUNX3 0.770 
HPP1 ESR1 0.755 
HPP1 MYOD1 0.773 
RUNX3 ESR1 0.754 
RUNX3 MYOD1 0.786 
ESR1 MYOD1 0.762 
P16 HPP1 RUNX3 0.764 
P16 HPP1 ESR1 0.753 
P16 HPP1 MYOD1 0.770 
P16 RUNX3 ESR1 0.754 
P16 RUNX3 MYOD1 0.771 
P16 ESR1 MYOD1 0.758 
HPP1 RUNX3 ESR1 0.761 
HPP1 RUNX3 MYOD1 0.776 
HPP1 ESR1 MYOD1 0.763 
RUNX3 ESR1 MYOD1 0.769 
P16 HPP1 RUNX3 ESR1 0.759 
P16 HPP1 RUNX3 MYOD1 0.773 
P16 HPP1 ESR1 MYOD1 0.761 
P16 RUNX3 ESR1 MYOD1 0.761 
HPP1 RUNX3 ESR1 MYOD1 0.765 
P16 HPP1 RUNX3 ESR1 MYOD1 0.763 
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Sites of patient recruitment 
Recruitment site Location Principle investigator Number of patients 
Addenbrooke's Hospital Cambridge Rebecca Fitzgerald 195 
University College London Hospital London Laurence Lovat 145 
Royal Victoria Infirmary Newcastle Michael Griffin 118 
Nottingham Queen's Medical Centre Nottingham Krish Ragunath 76 
Queen Alexandra Portsmouth 
  
Pradeep Bhandari 35 
South Tyneside NHS Foundation Trust South Tyneside Colin Rees 15 
University Hospital of North Tees Stockton-On-Tees Mathew Rutter 12 
University Hospital of North Durham County Durham and 
Darlington 
Anjan Dhar 12 
Queen Elizabeth II Hospital Welwyn Garden Danielle Morris 8 
St Mark's Hospital London, Northwick Park Adam Haycock 6 
North Tyneside General Hospital North Shields Stephen Attwood 5 
Hinchingbrooke Hospital Huntingdon Anita Gibbons 4 
Bedford Hospital Bedford Jacqueline Harvey 2 
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IHC staining conditions and antibodies used. 
Antigen Protocol Antigen 
retrieval 
Antibody Antibody  
dilution 
p53 Protocol F H1(30) NovocastraTM Mouse Monoclonal Antibody 
p53 Protein (DO-7) 
Product Code: NCL-p53-DO7 
1:50 
c-Myc MRC+E* H2(20) Epitomics c-MYC antibody, clone Y69, Rabbit monoclonal 
Cat #: 1472-1 
1:50 
Aurora 
kinase A 
MRC+E H2(30) Millipore Anti-Aurora-A (C-term), clone EP1008Y, Rabbit 
Monoclonal  
Cat #: 04-1037 
Lot specific dilution 
as the concentration 
is not normalised 
between lots 
* For c-Myc staining, the primary antibody was incubated with 60 minutes 
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Demographics, clinical history and molecular biomarkers included in the model selection. 
Selected predictor and interaction variables are highlighted in bold.   
  
 
Model input 
 
 
Options 
Demographics   
 Age  
 Gender M/F 
 BMI  
 Waist:hip ratio  
 Family history of EAC Y/N 
Smoking history   
 Current smoker Y/N 
 Total years smoked  
 Time since stopped smoking (years)  
 Number of pack-years  
Alcohol history   
 Number of alcohol units per week  
Medication history   
 Ever taken NSAIDs Y/N 
 Current NSAID status Currently taking, not taking, NA 
 NSAID dose frequency Never, on demand, at least daily, NA 
 NSAID duration (years)  
 Currently on H pylori medication Y/N, don’t know 
Symptoms   
 Chest pain Never, sometimes, often/daily 
 Burning chest Never, sometimes, often/daily 
 Acid taste in mouth Never, sometimes, often/daily 
 Number of years since heartburn started Never, <10 yrs, 10-20 yrs, >20 yrs 
Endoscopic findings   
 Hiatus hernia Y/N 
 Barrett’s oesophagus maximum length 
(cm) 
 
 Oesophagitis Y/N 
 Presence of oesophageal nodules or ulcers Y/N 
 Barrett’s oesophagus surveillance length 
(years) 
 
Biomarker panel on 
Cytosponge specimens 
  
 Glandular atypia 0/1 
 p53 IHC 0/1 
 TP53 mutation 0/1 
 p53 abnormality 0/1 
 cMYC IHC 0/1 
 Aurora Kinase A IHC 0/1 
 MYOD1 methylation (%)  
 RUNX3 methylation (%)  
 MYOD1+RUNX3 methylation (%)  
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Diagnosis follow-up of patients in the high, moderate, and low risk groups diagnosed with low-
grade dysplasia at baseline. 
 
Risk group Number of patients diagnosed 
with high grade dysplasia 
Total number of patients 
 
Percentage diagnosed with 
high grade dysplasia 
High risk 7 16 43.75% 
Moderate risk 7 29 24.10% 
Low risk  1 5 20% 
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Marginal effects of individual predictors. 
 
A marginal effect is a measure of the direct effect that a change in a particular biomarker, e.g. from 
negative to positive score, has on the predicted probability of having a high grade dysplasia, when the 
other predictors are kept fixed. All marginal effects were computed as in Greene27 using the R function 
"logitmfx" from R-cran library "mfx". 
 
Predictor Marginal effect Range 
 
Atypia 40% 19-61% 
p53 status 24% 10-38% 
Aurora kinase A 9% 1-17% 
log of interaction between age, maximal Barrett’s length, and obesity 8% 2-14% 
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Risk stratification prediction tool 
Predictor Type Vale Probability (P) Classification 
p53 abnormality 
(combination of IHC 
and mutation) 
Binary a  =1/(EXP(4.019+a*(-
1.802187)+b*(-
2.434713)+c*(-
0.8756866)+d*e*f*(-
0.00006342102))+1) 
Low risk P<0.0345 
Moderate risk 0.0345<P<0.48 
High risk P>0.48 
 
 
In MS Excel: 
=IF(P<0.0345,"Low 
Risk",IF(P>0.48,"High-Risk","Moderate-
Risk")) 
Glandular atypia Binary b 
AurKA staining Binary c  
Age Continuous d 
BMI Continuous e  
Maximal Barrett’s 
oesophagus length 
Continuous f  
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Biomarker profiles associated with Barrett’s segment length. Y–axis (M) refers to the maximum length of the Barrett’s segment. X-axis 0 or 1 refers to p53 
normality or abnormality respectively.   
